Last reviewed · How we verify
Nitazoxanide and Ciclésonide
Nitazoxanide and Ciclésonide is a Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently in Phase 2 development.
At a glance
| Generic name | Nitazoxanide and Ciclésonide |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitazoxanide and Ciclésonide CI brief — competitive landscape report
- Nitazoxanide and Ciclésonide updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI
Frequently asked questions about Nitazoxanide and Ciclésonide
What is Nitazoxanide and Ciclésonide?
Nitazoxanide and Ciclésonide is a Small molecule drug developed by ANRS, Emerging Infectious Diseases.
Who makes Nitazoxanide and Ciclésonide?
Nitazoxanide and Ciclésonide is developed by ANRS, Emerging Infectious Diseases (see full ANRS, Emerging Infectious Diseases pipeline at /company/anrs-emerging-infectious-diseases).
What development phase is Nitazoxanide and Ciclésonide in?
Nitazoxanide and Ciclésonide is in Phase 2.